| |
Insulin Resistance Raises Risk for Pancreatic Cancer, Study Finds
|
| |
| |
....In conclusion, our results support the hypothesis that higher insulin concentrations and insulin resistance may be a mechanism that explains the associations between diabetes mellitus, higher glucose concentration, and pancreatic cancer observed in previous studies....
Note From Jules LevIn: these study findings suggest another concern regarding long-term complications in HIV. Although studies have been conducted trying to identify the prevalence of diabetes among HIV+ individuals, little research has been conducted regarding ifdentifyong the prevalence of insulin resistance among HIV+. Are doctors testing everyonf with HIV for insulin resistance???? Of course not, get tested!!!
"PANCREATIC CANCER LINKED TO INSULIN RESISTANCE IN MALE SMOKERS"
".....This study supports the longstanding hypothesis that insulin is a growth promoter for pancreatic cancer....."
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
NIH News
National Cancer Institute (NCI)
http://www.cancer.gov/
A new study led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, shows for the first time that male smokers with the highest insulin levels are twice as likely to develop pancreatic cancer as men with the lowest levels. Similarly, men with glucose levels in the range of clinical diabetes were twice as likely to develop the cancer as men with normal glucose levels. This study examined data from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study* of 29,000 male smokers in Finland and appears in the December 14, 2005, issue of the "Journal of the American Medical Association"**.
Study investigators drew blood from enrollees when they joined the ATBC Study in the mid-1980s. This allowed the researchers to determine participants' overnight fasting insulin and glucose levels many years ahead of when they might be diagnosed with cancer. Over the course of 17 years, 169 men in the study developed pancreatic cancer.
Study results show a two-fold increase in risk of pancreatic cancer in the quartile of men with the highest fasting serum insulin levels
(greater than 6.1 microinternational units per milliliter) compared to
those in the lowest quartile (less than 2.75 microinternational units
per milliliter). Increasing concentrations of glucose, insulin, and
insulin resistance were also associated with pancreatic cancer.
Moreover, the risk for pancreatic cancer increased with longer follow-up time.
"Some men were in the highest quartile of insulin or had abnormal
glucose levels more than a decade before the cancer appeared," noted lead researcher Rachael Stolzenberg-Solomon, Ph.D., of NCI's Division of Cancer Epidemiology and Genetics. "It is important to note, however, that this study was only done in male smokers and that any assumptions about risk in the general population or whether one can determine their own pancreatic cancer risk specifically based on insulin levels is premature."
In their analysis, the researchers excluded men who developed pancreatic cancer within five years of having their blood drawn. This exclusion reduced the likelihood of including men whose elevated insulin levels may have been caused by undetected pancreatic tumors.
Smoking, aging, and perhaps obesity are the only known risk factors for pancreatic cancer, one of the most deadly cancers. Only 4 percent of people survive five years after being diagnosed with the disease. There are few treatments, and the cancer is frequently discovered only after a tumor has spread beyond the pancreas. It is estimated that 31,800 people in the United States -- including 15,820 men -- will die from pancreatic cancer in 2005.
Cancers of the colon, breast, liver, and pancreas are among those that tend to occur with type-2 diabetes among adults. Clinical diabetes is defined as glucose levels greater than or equal to 126 milligrams per deciliter. But epidemiologic studies on the subject are inconsistent, and researchers are only beginning to understand how the diseases might be related and how best to treat patients diagnosed with both type-2 diabetes and cancer. It is possible that type-2 diabetes could be related to pancreatic cancer through the growth regulatory effects of insulin. Few studies have been done specifically to understand how the diseases are related. Instead, researchers have focused largely on identifying cancers that occur with diabetes (or pre-diabetic states) and explaining why this happens.
This study supports the longstanding hypothesis that insulin is a growth promoter for pancreatic cancer. "This study of insulin levels gives us another important clue about the various influences that are probably important in the risk of developing pancreatic cancer, and possibly other cancers, particularly in smokers," said Demetrius Albanes, M.D., senior researcher for the NCI team.
The findings must be replicated in other groups, including women and non-smokers, but the results are consistent with other recent studies.
An earlier study in "JAMA"*** found that diabetes and elevated fasting glucose levels were independent risk factors for several major cancers, including pancreatic cancer, among 1.3 million Koreans. The participants were far leaner than those in studies involving Westerners. Noting that obesity was not a factor in the results, the researchers suggested that elevated insulin levels may account for the increased cancer risk.
In May 2005, an analysis of 36 studies involving diabetes and pancreatic cancer found a modest causal association between type-2 diabetes and the cancer. After obesity and smoking, diabetes may be the third modifiable risk factor for pancreatic cancer, the researchers concluded in the "British Journal of Cancer"****.
For more information about cancer, please visit the NCI Web site at
http://www.cancer.gov/ or call NCI's Cancer Information Service at
1-800-4 CANCER (1-800-422-6237).
The National Institutes of Health (NIH) -- "The Nation's Medical
Research Agency" -- includes 27 Institutes and Centers and is a
component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
**Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and
pancreatic cancer in male smokers, "JAMA"; 294(22).
***Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum
glucose level and cancer risk in Korean men and women. "JAMA" 2005; 293(2):194-202.
****Huxley R, Ansary-Moghaddam A, Berrington dG, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. "Br J Cancer" 2005; 92(11):2076-2083.
Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers
Rachael Z. Stolzenberg-Solomon, PhD; Barry I. Graubard, PhD; Suresh Chari, MD; Paul Limburg, MD; Philip R. Taylor, MD, ScD; Jarmo Virtamo, MD; Demetrius Albanes, MD
JAMA. Dec 14, 2005;294:2872-2878.
ABSTRACT
Context: Obesity, diabetes mellitus, and glucose intolerance have been associated with increased pancreatic cancer risk; however, prediagnostic serum insulin concentration has not been evaluated as a predictor of this malignancy.
Objective: To investigate whether prediagnostic fasting glucose and insulin concentrations and insulin resistance are associated with subsequent incidence of exocrine pancreatic cancer in a cohort of male smokers.
Design, Setting, and Participants: A case-cohort prospective study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (1985-1988) cohort of 29 133 male Finnish smokers ages 50 to 69 years. The study included 400 randomly sampled subcohort control participants and 169 incident pancreatic cancer cases that occurred after the fifth year of follow-up. All participants were followed up through December 2001 (up to 16.7 years of follow-up).
Main Outcome Measures: Incident exocrine pancreatic cancer identified from the Finnish Cancer Registry.
Results: After adjusting for age, smoking, and body mass index, higher baseline fasting serum concentrations of glucose, insulin, and insulin resistance were positively associated with pancreatic cancer. The presence of biochemically defined diabetes mellitus (glucose, 126 mg/dL [6.99 mmol/L]) and insulin concentration in the highest vs lowest quartile both showed a significant 2-fold increased risk (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.04-4.35; and HR, 2.01; 95% CI, 1.03-3.93; respectively). There were significant interactions for all the biomarker exposures by follow-up time, such that the positive associations were stronger among the cases that occurred more than 10 years after baseline (highest vs lowest quartile: glucose, HR, 2.16; 95% CI, 1.05-4.42; P for trend = .02; insulin, HR, 2.90; 95% CI, 1.22-6.92; P for trend = .005; and insulin resistance, HR, 2.71; 95% CI, 1.19-6.18; P for trend = .006).
Conclusions: These results support the hypothesis that exposure to higher insulin concentrations and insulin resistance predicts the risk of exocrine pancreatic cancer.
Introduction
Based on the findings from several retrospective and prospective observational studies, type 2 diabetes mellitus and glucose intolerance are fairly consistent, albeit somewhat controversial, risk factors for pancreatic cancer.1-5 This is because it has been unresolved whether diabetes mellitus is etiologically involved in pancreatic carcinogenesis or the result of subclinical malignancy. One biologically plausible mechanism whereby type 2 diabetes mellitus may be related to pancreatic carcinogenesis is through the growth-regulatory effects of insulin.6 Experimental studies show that insulin has growth promoting and mitogenic effects on pancreatic cancer cells7 and patients with type 2 diabetes mellitus are known to exhibit hyperinsulinemia during the early stages of their disease.8 The proposed hyperinsulinemia hypothesis is also indirectly supported by several studies of positive associations between obesity, lack of physical activity, and pancreatic cancer.9-14
We previously reported a significant 2-fold increased risk between self-reported diabetes mellitus and pancreatic cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study of male smokers.14 In this case-cohort study, we evaluated whether fasting serum insulin and glucose concentrations were prospectively associated with risk for incident pancreatic cancer. To reduce the potential influence of subclinical cancer on insulin and glucose concentrations, only participants alive and without clinical evidence of cancer during the first 5 years of cohort follow-up were included.
Author Comments
To our knowledge, this is the first study to show that higher prediagnostic fasting serum insulin and insulin resistance are associated with an increased risk for pancreatic cancer. The dose-response nature of the association, the 2-fold increase in risk of biochemically defined diabetes mellitus, and the substantially enhanced risk observed with longer follow-up support the veracity of our results.
Both the direction and magnitude of our findings confirm the positive association between higher glucose concentrations, biochemically defined diabetes mellitus, and pancreatic cancer reported in other prospective studies.2-5 The Paris Prospective Study (all men)5 with 17 years of follow-up and the Chicago Heart Association Detection Project in Industry cohort3 and Whitehall study (all men)4 both with 25 years of follow-up showed 2- to 5-fold increased relative risks for postload glucose-defined diabetes mellitus (glucose, 200 mg/dL [11.1 mmol/L]) and pancreatic cancer mortality.3-5 The Chicago Heart Association study3 demonstrated a significant positive linear association for postload glucose among men that corresponded with significant increased cancer risk with increasing BMI and serum uric acid levels; however, no association for these factors were observed in women. The Korean Cancer Prevention Study (KCPS), with 10 years of follow-up, showed a similar 1.5- to 2-fold increased pancreatic cancer risk with increased fasting serum glucose and biochemically defined diabetes mellitus (fasting glucose, 126 mg/dL [6.99 mmol/L]) for both men and women, and for both incident and fatal disease.2 The majority of participants in KCPS are considered lean by western standards and the associations between fasting glucose and pancreatic cancer were unchanged after controlling for BMI and did not vary by BMI.2 Body mass index is not associated with a greater pancreatic cancer risk in the ATBC study cohort despite the fact that approximately half of the population was overweight.14 In addition, in our study, the glucose, insulin, and insulin resistance associations became stronger after controlling for BMI, and similar to KCPS, BMI did not modify our associations. Smokers tend to be more insulin resistant and have higher insulin levels compared with nonsmokers, independent of obesity.20 In addition to BMI, our findings along with those of KCPS suggest that other factors independent of BMI may also contribute to the diabetes mellitus that is associated with pancreatic cancer.
The associations we observed for diabetes mellitus, insulin concentration, and insulin resistance are unlikely a consequence of pancreatic cancer, given our prospective study design that excluded cases diagnosed within the first 5 years after blood collection. Moreover, our associations for glucose, insulin, and insulin resistance were stronger among cases that occurred at least 10 years after baseline blood draw from which the insulin and glucose were determined. Most of the participants in the highest insulin quartile have normal concentrations that do not correspond with hyperinsulinemia (>14 ŹIU/mL [>97.2 pmol/L]). Given the close proximity of the exocrine pancreatic tissue to the islets of Langerhans, exocrine pancreatic cells are estimated to be exposed to insulin concentrations that are 20-fold higher than the systemic circulation, which some have hypothesized may potentially have implications for pancreatic cancer promotion.21 In vitro studies have shown that insulin promotes hamster, rat, and human pancreatic cancer cell lines.8, 21 In addition, a number of animal studies have shown that peripheral insulin resistance promotes ductal pancreatic carcinogenesis,22-27 and treatment with metformin, a drug used to treat glucose intolerance that specifically reduces insulin production, prevented the development of malignant lesions.27 The peripheral insulin resistance effect on pancreatic carcinogenesis in recently developed animal models, which more closely resemble human pancreatic cancer, however, have not yet been reported.28 These experimental studies support the biological plausibility of higher insulin concentrations and insulin resistance promoting pancreatic cancer development and our observed associations in humans.
In conclusion, our results support the hypothesis that higher insulin concentrations and insulin resistance may be a mechanism that explains the associations between diabetes mellitus, higher glucose concentration, and pancreatic cancer observed in previous studies.1-5,14 Although based solely on male smokers, our findings for glucose and biochemically defined diabetes mellitus are consistent with previous studies conducted in diverse populations that have included women and nonsmokers.2-5 As with any cause-specific analysis, competing causes of death were treated as censored at the time they occurred and assumed to be independent of occurrence of pancreatic cancer. If the censored events were related to occurrence of pancreatic cancer, there is potential for biased relative hazards. However, we have no reason to believe that such dependency exists, particularly because pancreatic cancer has few strong risk factors that result in higher mortality. The associations for insulin and insulin resistance reported herein require confirmation and along with observations of other studies1-5,14, 27 could potentially have important implications for nutrition and treatment-related cancer preventive strategies that modify or interfere with the insulin resistance pathway to help decrease the burden from this devastating disease. Lifestyle changes to decrease glucose and insulin concentrations through weight reduction, increasing physical activity, and diet, such as decreasing saturated fat intake, and identification of other modifiable factors that may contribute to higher glucose and insulin concentrations could possibly impact pancreatic cancer development, as well as other cancer and chronic disease.29-33
Results
Selected characteristics of the case and subcohort control participants are shown in Table 1. Compared with the subcohort control participants, case participants were older (P<.001), had smoked for more years (P = .002), tended to have higher fasting glucose concentrations (P = .06), and more often reported a history of diabetes mellitus (P = .07).
Table 2 shows the age-adjusted means and 95% CIs of selected baseline characteristics of the subcohort control participants, according to quartile of fasting serum insulin concentration. With increasing quartiles of fasting serum insulin concentration, the mean levels of serum glucose, insulin resistance, weight, BMI, protein, and total and saturated fat intake, and the proportion of participants reporting a history of diabetes mellitus all increased (all P.02), although the proportion of participants reporting living in a city (P = .04) and leisure activity of exercising to keep fit decreased (P = .02).
After adjustment for age, years of smoking, and BMI, higher concentrations of glucose, insulin, and insulin resistance tended to show positive dose-response associations with pancreatic cancer (all P for trend .05) (Table 3). Biochemically defined diabetes mellitus and the highest insulin quartile demonstrated significant 2-fold increased risks. There were significant interactions between quartile-categorized glucose, insulin, and insulin resistance and pancreatic cancer by follow-up time, such that risks were greater among the cases that occurred with longer follow-up time (Figure). There was no interaction of the association between glucose, insulin, or insulin resistance and pancreatic cancer by BMI, smoking intensity and duration, alcohol intake, or trial intervention group, or interaction of the association for biochemically defined diabetes mellitus by follow-up time. Exclusion of participants who fasted less than 12 hours before blood collection and self-reported diabetes mellitus did not substantially change our results.
Methods
Study Population
The ATBC Study was a double-blind, placebo-controlled, 2 x 2 factorial design, primary prevention trial that tested whether -tocopherol or beta carotene could reduce the incidence of cancer among male smokers. Study rationale, design, and methods have been previously described.15 Between 1985 and 1988, 29 133 eligible men in southwestern Finland aged 50 to 69 years who smoked at least 5 cigarettes per day were randomized to receive active supplements (50 mg/d of -tocopherol, 20 mg/d of beta carotene, or both) or placebo. Men were excluded from the study if they had a history of malignancy other than nonmelanoma cancer of the skin or carcinoma in situ, severe angina on exertion, chronic renal insufficiency, liver cirrhosis, chronic alcoholism, or other medical conditions that might limit long-term participation; or if they were receiving anticoagulant therapy or used supplements containing vitamin E (>20 mg/d), vitamin A (>20 000 IU/d), or beta carotene (>6 mg/d). All participants provided written informed consent before randomization into the study. The study was approved by the institutional review boards of both the National Public Health Institute, Helsinki, Finland, and the US National Cancer Institute, Bethesda, Md.
Participants completed questionnaires on general background characteristics, including medical, smoking, dietary, and physical activity history during their prerandomization baseline visit.15 Trained study staff measured height and weight at baseline using standard methods. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Diet was assessed with a validated self-administered dietary history questionnaire that determined the frequency of consumption and usual portion size of 276 food items during the past year, using a color picture booklet as a guide for portion size.16
Selection of Case and Control Participants
To reduce the potential influence of subclinical cancer on insulin and glucose concentrations, all participants were alive and without clinical evidence of cancer during the first 5 years of cohort follow-up. Cases of pancreatic cancer occurring after their fifth year of cohort follow-up through December 2001 were identified from the Finnish Cancer Registry, which provides almost 100% case ascertainment in Finland.17 As their etiology may be different from the exocrine tumors, islet cell carcinomas (International Classification of Diseases, Ninth Revision [ICD-9] code 157.4 and ICD, 10th Revision [ICD-10] code C254) were excluded. During the follow-up period, 169 exocrine pancreatic cancer cases (ICD-9 code 157 and ICD-10 code C25) were confirmed. We selected a random sample of 400 participants among all eligible cohort members alive without a cancer diagnosis as of 5 years of follow-up or subcohort control participants as the comparison group. The interval between serum collection and follow-up was up to 16.7 years (median follow-up time for diagnosis, 13.8 years).
Biomarkers
At their prerandomization visit, study participants had a venipuncture for serum after an overnight fast and serum was stored in the dark at -70C. Frozen baseline serum samples were assayed for insulin and glucose concentration using the 2-site immunoenzymatic assay performed on an automated immunoassay system (Access, Beckman Instruments, Chaska, Minn) and a chemical analyzer and the hexokinase reagent (Hitachi 912 Chemistry Analyzer, Boehringer Mannheim, Indianapolis, Ind), respectively. Laboratory personnel were blinded to case and control sample status. Insulin resistance was estimated by using the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) formula {[fasting insulin (mIU/L) x fasting glucose (mmol/L)]/22.5}.18
In 2000, 93 participants with incident pancreatic cancer that occurred through 1997 and the 400 subcohort control participants had glucose and insulin values measured. In 2004, we measured glucose and insulin values at the same laboratory on an additional 76 case participants that occurred through 2001 to increase the sample size and power of the study. Blinded replicate quality control phantom samples from a pooled sample were placed randomly in all batches. Among the samples run in 2000, quality controls were 10% of each batch and had coefficient of variation percentages of less than 5% for both glucose and insulin. For the samples run in 2004, 27% of the samples tested were from our quality control pool. Unthawed samples from the same pooled quality control serum used in the batches run in 2000 were randomly placed throughout the 2004 study samples. Unthawed vials from 8 participants from the ATBC study who were control participants in the original study were also randomly placed throughout the study samples. Using a nested components of variance analysis, with logarithmically transformed quality control measurements across all batches,19 the estimated overall (intrabatch and interbatch) coefficient of variation percentages of the assays for glucose and insulin were 2.46% and 4.83%, respectively. The interbatch coefficient of variation percentage for the repeated measurements on the 8 control participants was 2.22% for glucose and 4.25% for insulin. Given the low coefficient of variation percentage calculated from our quality control study, we were confident that there were no differences in the measurements of glucose or insulin measured at the 2 times.
Statistical Analysis
We compared the distribution of the characteristics of the case and subcohort control participants for continuous variables using the Wilcoxon rank sum test and for categorical variables using asymptotic 2 test. Generalized linear models and logistic regression adjusted for age, continuous factors, and proportions, respectively, were used to calculate means and 95% confidence intervals (CIs) of the cohort characteristics among the control participants by fasting serum insulin quartile to help identify potential confounders. SAS software version 8.2 (SAS Institute Inc, Cary, NC) was used for these analyses.
To account for the differential sample rates of the case and subcohort control participants in a survival analysis, we used SUDAAN software version 9.0 (Research Triangle Institute, Research Triangle Park, NC) to perform weighted Cox proportional hazards regression analyses in which each participantfs weight was the inverse of their sample fraction. Case participants were given weights of 1 because they were sampled with certainty and the subcohort control participants had weights of 61.77 (24 708/400). By chance, as pancreatic cancer is relatively rare, none of the subcohort sample developed pancreatic cancer during follow-up. In the survival analysis, follow-up time was used as the underlying time metric to calculate hazard ratios (HRs) and 95% CIs. Using age as an underlying time metric in the survival analysis to more tightly control for age conferred similar HRs; however, we chose to use the follow-up time metric to evaluate the effects of latent disease with stratified analyses by follow-up time. Serum glucose, insulin, and insulin resistance were categorized in quartiles based on the distribution of the control participants. Biochemically defined diabetes mellitus was defined as a glucose concentration of at least 126 mg/dL (6.99 mmol/L). Dose response trends were tested using a score variable based on the median value of each category. Multivariable models were developed for serum glucose, insulin, and insulin resistance by individually adding potential confounders into the model, which included baseline age at randomization; height, weight, and BMI; smoking history (years of smoking, cigarettes smoked per day, and pack-years); urban living; education; self-reported medical history of gallstones, pancreatitis, peptic and duodenal ulcers, and diabetes mellitus; trial intervention group (-tocopherol or beta carotene); occupational and leisure activity; and dietary energy, energy-adjusted protein, fat, saturated fat, carbohydrate, fiber, starch, free sugars, sucrose, zinc, calcium, and folate intake, and alcohol consumption. Although none of the smoking variables were confounders of our associations in our smoker population, smoking duration was included in our models because smoking is a putative risk factor for pancreatic cancer. Other variables were included in the final model if they were associated with both the risk factor and the disease, changed the risk estimate to at least 10%, had P.20 in the full model, and/or increased the precision of the risk estimate. The final multivariable models included continuous variables for age, years of smoking, and BMI.
We used a case-cohort design rather than a matched-nested, case-control design because it allows use of time-to-disease data and provides an unbiased estimate of the HR in our population. It also enabled us to examine interactions by time, which was one of our study goals. Because all participants in our study were smokers, the potentially relevant matching factors for which our cases differed from the subcohort control participants were age and smoking duration (years of smoking). We controlled for these differences by including both variables as covariates in the Cox proportional hazards regression analysis, as one would in a cohort study. This model adjustment approach worked especially well for our analysis because there was substantial overlap between our case and subcohort control participants in the distributions of these variables.
Effect modification of glucose, insulin, and insulin resistance by BMI, smoking intensity and duration, alcohol intake, trial intervention group, and follow-up time was tested through cross-product terms in multivariable models by using the serum biomarkers trend variables and dichotomized BMI, smoking, alcohol (based on the median split), and follow-up time from baseline (<8 years and 8, 10, 12, and 14 years, respectively). Analyses stratified by follow-up time were also conducted. All statistical tests were 2-sided and considered statistically significant at P.05.
|
|
| |
| |
|
|
|
